Written by Douglas Feil, NBCF Chief Program Officer Disclaimer: The information provided in this article is for...
Basiran
De-Escalating Treatment: The CompassHER2-pCR Trial and the Future of Personalized Breast Cancer Care
De-Escalating Treatment: The CompassHER2-pCR Trial and the Future of Personalized Breast Cancer Care
The landscape of oncology is currently undergoing a seismic shift, moving away from the "one-size-fits-all" approach toward...
For the pharmaceutical industry, the “patent cliff” is no longer a theoretical concern relegated to long-term risk...
In the landscape of modern drug discovery, the traditional paradigm of preclinical testing is undergoing a profound...
Norman, OK – In a significant leap forward for cancer research, scientists at the University of Oklahoma...
The landscape of drug discovery is undergoing a seismic shift. For decades, the gold standard of preclinical...
In the landscape of modern drug discovery, a profound paradigm shift is underway. For decades, the pathology...
Introduction: Beyond the Parade For many, the annual Pride parade is a vibrant tapestry of color, celebration,...
NEW YORK, NY – As the calendar turns to October, the world is often awash in a...
By Editorial Staff, based on insights from Douglas Feil, NBCF Chief Program Officer Medical Disclaimer: The information...
